ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2121

A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab

Yoshiya Tanaka1, Kentaro Hanami2, Hisashi Tasaka1, Shunsuke Fukuyo1, Douglas J. Haney3, Nadine Defranoux3, Rebecca Bolce3, Guy Cavet3, David Chernoff3, Kunihiro Yamaoka1, Kazuyoshi Saito1 and Shintaro Hirata1, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2The First Department of Internal Medicinei, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3Crescendo Bioscience Inc., South San Francisco, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Activity score, Biomarkers, rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The multi-biomarker disease activity (MBDA) score assessed with 0.2 mL serum has been reported as a novel composite disease activity index for patients with rheumatoid arthritis (RA). We reported the correlation of MBDA score with conventional composite measures such as DAS28 in patients with RA. However, the estimation of the MBDA score in RA patients treated with anti-IL-6 receptor antibody tocilizumab (TCZ) has not been investigated. Purpose of this study is to clarify if the MBDA score could reflect disease activity and track therapeutic effect including clinical and radiographic outcomes in RA patients treated with TCZ.

Methods:

Fifty two RA patients who treated with TCZ were enrolled. The MBDA algorithm combines 12 serum biomarkers (VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, MMP-1, MMP-3, YKL-40, Leptin, Resistin, CRP, SAA) into a single score from 1-100 according the Vectra™ DA algorithm. MBDA disease activity categories were defined as high (HDA>44), moderate (MDA>29≤44), low (LDA<25≤29) and remission (REM≤25). Radiographic changes were assessed by the modified total Sharp score (mTSS). For statistic analysis, Spearman's rank correlation coefficients and Pearson's chi-square test were used. All p-values are two sided and <0.05 were considered significant.

Results:

At baseline (BL), patients had median age of 57±18, disease duration of 12.4±11.2 years, DAS28 of 5.6±1.3, CDAI of 22.1±12.2, HAQ-DI of 1.4±0.9 and mTSS of 106±112. MTX was used in 86.5% and positivity of RF was 78.8%. MBDA score at BL was 57.7±19.2 and were correlated well with DAS28 and CDAI (ρ=0.63 and 0.57, respectively, p<0.0001). TCZ improved MBDA score from 57.7 to 43.7 and 42.5 at W24 and W52, respectively, DAS28 from 5.6 to 2.5 and 2.9, CDAI from 22.2 to 6.4 and 5.6, at BL, W24 and W52, respectively. Changes of MBDA from BL to 52W by TCZ were significantly correlated with those of DAS28 (r=0.471, p<0.001) and CDAI (r=0.373, p<0.01). MBDA-REM ratio at W52 was significantly correlated with DAS28-REM ratio (AUROC=0.643) and CDAI-REM ratio (0.768). Yearly progression of mTSS (ΔmTSS) was improved from 12.3±14.9 to 0.5±2.5 by TCZ and 77% achieved ΔmTSS<0. Interestingly, all patients who achieved MBDA-LDA (8), MBDA-REM (3) or Boolean-REM (5) at W24 showed ΔmTSS<0.5, whereas some of DAS28-REM and CDAI-REM did ΔmTSS>0.5. Patients who achieved MBDA-REM or Boolean-REM at W24 revealed higher likelihood ratio for achieving both radiographic and functional REM at W52 than those who DAS28-REM and CDAI-REM. 

Conclusion:

This is the first report of the MBDA estimated in RA patients treated with TCZ. TCZ efficiently improved MBDA score and BL and changes of MBDA were correlated with those of conventional composite measures. Although additional data are needed to assess the relationship between MBDA and radiographic and functional remission, The MBDA score reflects disease activity and tracks therapeutic effects and MBDA-REM might be preferable to DAS28-REM for predicting good outcome in both radiographic damage and physical function in RA patients treated with TCZ.


Disclosure:

Y. Tanaka,

Mitsubishi-Tanabe Pharma Corporation, Abbott Japan Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Santen Pharmaceutical Co., Ltd., Pfizer Japan Inc., Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., GlaxoSmithKlin,

8,

Bristol-Myers Squibb, MSD K.K., Chugai Pharmaceutical Co., Ltd., Mitsubishi-Tanabe Pharma Corporation, Astellas Pharma Inc., Abbott Japan Co., Ltd., Eisai Co., Ltd. and Janssen Pharmaceutical K.K,

2;

K. Hanami,
None;

H. Tasaka,

Chugai Pharmaceutical Co. Ltd.,

3;

S. Fukuyo,
None;

D. J. Haney,

Crescendo Bioscience Inc.,

3;

N. Defranoux,

Crescendo Bioscience Inc.,

3;

R. Bolce,

Crescendo Bioscience Inc.,

3;

G. Cavet,

Crescendo Bioscience Inc.,

3;

D. Chernoff,

Crescendo Bioscience Inc.,

3;

K. Yamaoka,
None;

K. Saito,
None;

S. Hirata,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-multi-biomarker-disease-activity-vectra-da-algorithm-score-reflects-clinical-disease-activity-and-structural-changes-in-rheumatoid-arthritis-patients-treated-with-tocilizumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology